BioElectronics Corp. (OTCPK:BIEL), the maker of ActiPatch™, the drug free anti-inflammatory patch, with an embedded battery operated microchip delivering continuous pulse therapy that revolutionizes the way people heal, today announced that Emerging Growth Research, LLP has issued a Buy recommendation on the company's shares through a new research report on the company. The report, which places a12-month target price of $0.20 on the company's shares, outlines the research firm's belief that the Company's sales are aggressively ramping and that positive clinical data is expected over the next few months. The report can be viewed online at www.wallstreetreportonline.com.
Andrew Whelan, CEO and President of BioElectronics Corp. commented, "We are very pleased to have received such a positive rating in this research report. The management team at BioElectronics is very excited about the positive developments taking place at the company, especially relating to our international distribution. Over the past few months shipments to our international distributors have substantially increased. We believe this is a trend that is likely to continue allowing us to report record revenue levels over the coming quarters. We continue to believe the future is very bright for our company and its shareholders."